PCC AI Genomic Immune Factors - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  PCC AI Genomic Immune Factors

Pancreatic Cancer Collective Research Team: Computational Approaches To Identifying High-Risk Pancreatic Cancer Populations – Identification of Genomic and Immune Factors in High-Risk Populations for Pancreatic Cancer

Grant Term: May 2019–February 2022

This interdisciplinary, multi‐institutional, and international team will focus on developing a collection of biomarkers that predict an individual’s risk of developing pancreatic cancer. Samples will be obtained from large clinical and molecular datasets, and the research will be complemented by the identification of tumor microenvironmental factors to create a screening tool for pancreatic cancer risk.

Supported by:

ABOUT THIS TEAM’S RESEARCH

This team will develop a collection of biomarkers for pancreatic cancer which will be obtained from large clinical and molecular datasets with multiple cohorts. Specifically, they will look at rare gene variants, or modifications of the DNA, in specific regions which, when analyzed together, will predict an individual’s risk of developing pancreatic cancer. The datasets include the UK Biobank, European Study on Digestive Illnesses and Genetics, The Cancer Genome Atlas, and International Cancer Genome Consortium. This approach will be complemented with the examination of tumor microenvironmental factors which are associated with pancreatic cancer risk, including gene expression patterns and response to bacterial and viral infections. This is a high-risk, high-reward project that, if successful, will integrate clinical, genetic, and microenvironmental factors to revolutionize screening and risk-prediction for pancreatic cancer.

This team is part of the Pancreatic Cancer Collective, an initiative of Lustgarten Foundation for Pancreatic Cancer Research and Stand Up To Cancer.

MEET THE TEAM

The top scientists and researchers on the Computational Approaches To Identifying High-Risk Pancreatic Cancer Populations Identification of Genomic and Immune Factors in High-Risk Populations Research Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the Computational Approaches To Identifying High-Risk Pancreatic Cancer Populations Identification of Genomic and Immune Factors in High-Risk Populations Research Team.

Research Team Members

Raul Rabadan, PhD, MSc
Columbia University
Leader

Núria Malats, MD, MPH, PhD
Spanish National Cancer Research Centre (CNIO)
Co-leader

Ken Olive, PhD
Columbia University
Principal

Tal Korem, PhD
Columbia University
Principal

Gulam Manji, MD, PhD
Columbia University
Principal

Ioan Filip
Columbia University
Project Manager

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and six-monthly reviews by senior scientists. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. For the Identification of Genomic and Immune Factors in High-Risk Populations for Pancreatic Cancer team, please click on the link to see summaries of their research results so far.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in March 2019; links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

LEARN MORE

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.